Biomarker and Companion Diagnostics Annual 2 Day Conference - London, United Kingdom (March 7-8th, 2024)
03 Jan 2024
DUBLIN, Jan. 3, 2024 /PRNewswire/ -- The "5th Annual Biomarker and Companion Diagnostics Conference" has been added to
ResearchAndMarkets.com's offering.
Leveraging Next-Gen Technologies Beyond Conventional Biomarker Drug Discovery
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS-based CDx and the Importance of imaging biomarkers for precision medicine.
Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in a one-on-one session.
Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker
The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th - 8th March 2024 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area.
The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Key Highlights:
Clinical biomarker identification and qualification
Biomarkers and personalized medicine
Assay development and validation
NGS and novel technologies in biomarker discovery
Commercialization of biomarkers in therapeutic and CDx applications
Speakers
Debora Souza Da Costa, Biosample Operations Specialist, Roche
Stephanie Traub, Associate Director, Translational Biomarkers & Bioanalysis, UCB
Ron Wolbert, Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis, UCB
Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB
Smiths Lueong, Head, Early Detection and Biomarkers, The Cameroon Consortium for Translational Cancer Research
Christian Garde, Scientific Director, Bioinformatics, Evaxion Biotech A/S
Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG
Shidong Jia, Founder, CEO, Predicine
Liying Yan, President, Scientist, EpigenDx
Robert Watson, Clinical Lecturer, University of Oxford
Radha Krishnan, Executive Director and Clinical Pathology Lead, Merck
Jelmar Quist, Cancer Bioinformatician, King's College London
Jessica Fowler, Market Development Executive, Roche
Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby
Christopher Peters, Clinical Senior Lecturer, Imperial College London
For more information about this conference visit https://www.researchandmarkets.com/r/j85161
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.